Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Non-Current Debt (2019 - 2025)

Historic Non-Current Debt for Tg Therapeutics (TGTX) over the last 7 years, with Q3 2025 value amounting to $245.3 million.

  • Tg Therapeutics' Non-Current Debt rose 48.41% to $245.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.3 million, marking a year-over-year increase of 48.41%. This contributed to the annual value of $244.4 million for FY2024, which is 14414.09% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Non-Current Debt is $245.3 million, which was up 48.41% from $245.0 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Non-Current Debt high stood at $245.3 million for Q3 2025, and its period low was $66.8 million during Q4 2021.
  • Moreover, its 5-year median value for Non-Current Debt was $99.5 million (2023), whereas its average is $135.4 million.
  • In the last 5 years, Tg Therapeutics' Non-Current Debt skyrocketed by 76557.8% in 2021 and then soared by 48.41% in 2025.
  • Over the past 5 years, Tg Therapeutics' Non-Current Debt (Quarter) stood at $66.8 million in 2021, then increased by 6.51% to $71.1 million in 2022, then surged by 40.74% to $100.1 million in 2023, then surged by 144.14% to $244.4 million in 2024, then rose by 0.37% to $245.3 million in 2025.
  • Its last three reported values are $245.3 million in Q3 2025, $245.0 million for Q2 2025, and $244.7 million during Q1 2025.